Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes

Insulin‐like growth factor 2 (IGF2) and the transformation related protein 53 (Trp53) are potent regulators of cell growth and metabolism in development and cancer. In vitro evidence suggests several mechanistic pathway interactions. Here, we tested whether loss of function of p53 leads to IGF2 ligand pathway dependency in vivo. Developmental lethality occurred in p53 homozygote null mice that lacked the paternal expressed allele of imprinted Igf2. Further lethality due to post‐natal lung haemorrhage occurred in female progeny with Igf2 paternal null allele only if derived from double heterozygote null fathers, and was associated with a specific gene expression signature. Conditional deletion of Igf2fl/fl attenuated the rapid tumour onset promoted by homozygous deletion of p53fl/fl. Accelerated carcinoma and sarcoma tumour formation in p53+/− females with bi‐allelic Igf2 expression was associated with reductions in p53 loss of heterozygosity and apoptosis. Igf2 genetic dependency of the p53 null phenotype during development and tumour formation suggests that targeting the IGF2 pathway may be useful in the prevention and treatment of human tumours with a disrupted Trp53 pathway.

[1]  W. Blattner,et al.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome , 1990, Nature.

[2]  C. Prives,et al.  Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.

[3]  R. Jaenisch,et al.  DNA hypomethylation can activate Xist expression and silence X-linked genes. , 1996, Genes & development.

[4]  Mary F. Lopez,et al.  Igf2 deficiency results in delayed lung development at the end of gestation. , 2006, Endocrinology.

[5]  James D. Brenton,et al.  Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer , 2008, Human molecular genetics.

[6]  Douglas Hanahan,et al.  Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy , 2010, Proceedings of the National Academy of Sciences.

[7]  C. Purdie,et al.  Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.

[8]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[9]  L. Donehower Does p53 affect organismal aging? , 2002, Journal of cellular physiology.

[10]  S. Baker,et al.  PTEN and the PI3-kinase pathway in cancer. , 2009, Annual review of pathology.

[11]  M. Mclaughlin,et al.  Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression , 2011, Cell.

[12]  A. Hassan,et al.  Insulin-like Growth Factor II Supply Modifies Growth of Intestinal Adenoma in ApcMin/+ Mice , 2000 .

[13]  Melinda Larsen,et al.  Fibronectin requirement in branching morphogenesis , 2003, Nature.

[14]  R. Jaenisch,et al.  Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. , 2007, Genes & development.

[15]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Levine,et al.  The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. , 2010, Trends in cell biology.

[17]  Masahiro Sato,et al.  The expression profile of microRNAs in mouse embryos , 2006, Nucleic acids research.

[18]  M. Kaufman,et al.  High-frequency developmental abnormalities in p53-deficient mice , 1995, Current Biology.

[19]  L. Mayo,et al.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Gabory,et al.  The H19 locus acts in vivo as a tumor suppressor , 2008, Proceedings of the National Academy of Sciences.

[21]  L. Donehower,et al.  Genetic background alters the spectrum of tumors that develop in p53‐deficient mice , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  Laurent Journot,et al.  H19 acts as a trans regulator of the imprinted gene network controlling growth in mice , 2009, Development.

[23]  A. Levine,et al.  The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. , 2007, Cancer research.

[24]  Zhihui Feng,et al.  DNA Damage Induces p53-dependent BRCA1 Nuclear Export* , 2004, Journal of Biological Chemistry.

[25]  S. Tilghman,et al.  Disruption of imprinting caused by deletion of the H19 gene region in mice , 1995, Nature.

[26]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[27]  A. Hassan,et al.  Insulin-like growth factor II supply modifies growth of intestinal adenoma in Apc(Min/+) mice. , 2000, Cancer research.

[28]  D. Hanahan,et al.  A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis , 1994, Nature.

[29]  Graziano Pesole,et al.  Pscan: finding over-represented transcription factor binding site motifs in sequences from co-regulated or co-expressed genes , 2009, Nucleic Acids Res..

[30]  R. Weinberg,et al.  Tumor spectrum analysis in p53-mutant mice , 1994, Current Biology.

[31]  S. Velasco-Miguel,et al.  Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.

[32]  J. Harper,et al.  Insulin‐like growth factor ligands, receptors, and binding proteins in cancer , 2005, The Journal of pathology.

[33]  R. Jaenisch,et al.  Induction of Tumors in Mice by Genomic Hypomethylation , 2003, Science.

[34]  E. Jones,et al.  Kinetics of insulin-like growth factor II (IGF-II) interaction with domain 11 of the human IGF-II/mannose 6-phosphate receptor: function of CD and AB loop solvent-exposed residues. , 2006, Journal of molecular biology.

[35]  Eduardo Sontag,et al.  Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.

[36]  Arnold J Levine,et al.  A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. , 2010, Cancer cell.

[37]  A. Hassan,et al.  Cell survival and proliferation are modified by insulin-like growth factor 2 between days 9 and 10 of mouse gestation. , 2001, Development.

[38]  A. Efstratiadis,et al.  Parental imprinting of the mouse insulin-like growth factor II gene , 1991, Cell.

[39]  T. Mak,et al.  Regulation of PTEN transcription by p53. , 2001, Molecular cell.

[40]  J. Beyene,et al.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. , 2011, The Lancet. Oncology.

[41]  A. El‐Naggar,et al.  Multiple stress signals activate mutant p53 in vivo. , 2011, Cancer research.

[42]  F. Kashanchi,et al.  Regulation of insulin-like growth factor II P3 promotor by p53: a potential mechanism for tumorigenesis. , 1996, Cancer research.

[43]  Michael Karin,et al.  p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling , 2009, Cell.

[44]  C. McKerlie,et al.  Respiratory Distress and Neonatal Lethality in Mice Lacking Golgi α1,2-Mannosidase IB Involved in N-Glycan Maturation* , 2007, Journal of Biological Chemistry.

[45]  J. Marine,et al.  Mdm2-mediated ubiquitylation: p53 and beyond , 2010, Cell Death and Differentiation.

[46]  Hiroyuki Yamamoto,et al.  IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. , 2010, Carcinogenesis.

[47]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[48]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[49]  H. Scrable,et al.  Delta40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs. , 2010, Genes & development.

[50]  Sook Y. Lee,et al.  Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma , 2000, Oncogene.

[51]  Charmaine D. Wilson,et al.  Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations , 2010, PloS one.

[52]  L. Donehower,et al.  Timed Somatic Deletion of p53 in Mice Reveals Age-Associated Differences in Tumor Progression , 2009, PloS one.

[53]  Elizabeth J. Robertson,et al.  Role of insulin-like growth factors in embryonic and postnatal growth , 1993, Cell.

[54]  S. Shete,et al.  Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. , 2006, Cancer research.

[55]  Li-fraumeni syndrome. , 2007, Genes & cancer.

[56]  D. Page,et al.  Zfx mutation results in small animal size and reduced germ cell number in male and female mice. , 1997, Development.

[57]  C. Harris,et al.  The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.

[58]  B. Cullen,et al.  The imprinted H19 noncoding RNA is a primary microRNA precursor. , 2007, RNA.

[59]  R. Kuick,et al.  Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. , 2009, The Journal of clinical endocrinology and metabolism.

[60]  Alberto Inga,et al.  The expanding universe of p53 targets , 2009, Nature Reviews Cancer.

[61]  A. Yang,et al.  REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. , 2002, Molecular cell.

[62]  L. Donehower Longevity regulation in flies: A role for p53 , 2009, Aging.

[63]  B. Sohn,et al.  Deregulation of DNA methyltransferases and loss of parental methylation at the insulin‐like growth factor II (Igf2)/H19 loci in p53 knockout mice prior to tumor development , 2005, Journal of cellular biochemistry.

[64]  Pan Du,et al.  lumi: a pipeline for processing Illumina microarray , 2008, Bioinform..

[65]  Gerard I. Evan,et al.  Modeling the Therapeutic Efficacy of p53 Restoration in Tumors , 2006, Cell.

[66]  F. Kashanchi,et al.  p53 regulates human insulin-like growth factor II gene expression through active P4 promoter in rhabdomyosarcoma cells. , 1998, DNA and Cell Biology.

[67]  G. Sauvageau,et al.  Zfx: At the Crossroads of Survival and Self-Renewal , 2007, Cell.

[68]  L. Strong,et al.  Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.

[69]  S. Avnet,et al.  Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. , 2009, Cancer research.

[70]  B. Alman,et al.  Gli2 and p53 cooperate to regulate IGFBP-3- mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. , 2009, Cancer cell.

[71]  A. Harris,et al.  Igf2 ligand dependency of Pten+/− developmental and tumour phenotypes in the mouse , 2011, Oncogene.

[72]  C. Croce,et al.  Oncogenic role of miR-483-3p at the IGF2/483 locus. , 2010, Cancer research.

[73]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[74]  S. Kornfeld,et al.  Mannose 6-phosphate receptors: new twists in the tale , 2003, Nature Reviews Molecular Cell Biology.

[75]  A. Efstratiadis,et al.  A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting , 1990, Nature.

[76]  Shirley M. Taylor,et al.  p53-mediated repression of DNA methyltransferase 1 expression by specific DNA binding. , 2003, Cancer research.

[77]  D. Hanahan,et al.  Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. , 2002, Cancer cell.

[78]  H. Werner,et al.  Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[79]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[80]  D. Hanahan,et al.  Deregulation of both imprinted and expressed alleles of the insulin–like growth factor 2 gene during β–cell tumorigenesis , 1995, Nature Genetics.